The incidence of type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD) has significantly increased worldwide in recent decades, and improved treatments for T2DM and DKD are urgently needed. The pathogenesis of aging-related disorders, such as T2DM and DKD, involves multiple mechanisms, including inflammation, autophagy impairment, and oxidative stress, which are closely associated with mitochondrial dysfunction. Therefore, mitochondrial quality control may be a novel therapeutic target for T2DM and DKD. Previous reports have shown that members of the mammalian Sirtuin family, SIRT 1–7, which are recognized as antiaging molecules, play a crucial role in the regulation of mitochondrial function and quality control through the modulation of oxidative stress, inflammation and autophagy. In this review, we summarized the research published in recent years to highlight the role of Sirtuins in mitochondrial quality control as a therapeutic target for T2DM and DKD.

最近几十年来，全球范围内2型糖尿病（T2DM）和糖尿病肾病（DKD）的发病率显着增加，迫切需要改进T2DM和DKD的治疗方法。诸如T2DM和DKD等与衰老相关的疾病的发病机制涉及多种机制，包括炎症，自噬功能障碍和氧化应激，这与线粒体功能障碍密切相关。因此，线粒体质量控制可能是T2DM和DKD的新型治疗靶标。先前的报道表明，哺乳动物Sirtuin家族成员SIRT 1-7被认为是抗衰老分子，通过调节氧化应激，炎症和自噬，在调节线粒体功能和质量控制中起着至关重要的作用。在这篇评论中